iVision Tech Issues Minibonds in Tranches, Up To 5 Million, with the Support of CrowdFundMe and Fundera

iVision Tech SpA , an innovative and leading SME in Made in Italy, specialized in the design and production of luxury eyewear, has structured a minibond to be used in tranches up to a total of 5 million.

The structure of the minibond

The placement will begin in the current month of October and will also be aimed at retail investors, as well as, obviously, institutional investors. The coupons, semi-annual, recognize investors a spread of up to 300 bpa on the 6-month Euribor.

The company has been rated BB by Modefinance, the first Italian fintech to be authorized to operate as a credit rating agency.

CrowdFundMe , a crowdfunding portal listed on Piazza Affari, will provide its support for the placement which will take place on the Fundera portal , while the issue was structured with the support of the Advisor Frigiolini & Partners Merchant.

The funds raised will be gradually used by iVision Tech to consolidate the business model, expand the offering and improve penetration in international markets, also through the acquisition of strategic brands.

The collaboration between Crowdfundme and Fundera-Frigiolini & Partners

At the end of 2023, CrowdFundMe had signed an agreement with the similar portal Fundera, controlled by Frigiolini & Partners Merchant, to channel its interested customers directly to the Fundera platform.

In this way, potential subscribers, including retail ones, have the opportunity to subscribe on Fundera to minibonds specifically selected by CrowdFundMe from among those published, including that of iVision.

This modality, hinged between two portals recently authorized under the new European legislation, allows CrowdFundMe customers, having carried out the necessary checks required by the legislation, to access coupon-yielding bond instruments, diversifying the portfolio and supporting the real economy.

iVision Tech: technology for Eyewear

iVision Tech is divided into two main divisions: “iVision Eyewear”, specialized in the production of glasses in various ways (subcontract, full subcontract and semi-finished), and “iVision R&D”, dedicated to the research and development of innovative technological solutions, including the patented “iSee” project for the blind and visually impaired.

The company has also been active in the retail market since 2023, thanks to the Henry Jullien brand, a historic French brand renowned for its Doublé Or technique, which involves gold coating the frames.

In 2023, iVision Tech recorded a turnover of 9.37 million euros, up 18.6% compared to the previous year. The company boasts a positive EBITDA of 12.6% and a solid net financial debt of 2.88 million.

Growth and acquisitions following the IPO

The stock has also gained 5.5% in the last year, demonstrating the market’s appreciation for the growth path undertaken.

In 2024, iVision Tech further expanded its international presence with the acquisition of 60% of the Bulgarian company IVILENS OOD, a manufacturer of ophthalmic lenses, and 51% of Teknoema Srl, active in engineering and manufacturing services for the EMS (Electronics Manufacturing Services) sector.

“The results of the first half of the year – the company pointed out – significantly highlight that we are on the right track: the 15% Ebitda margin and the value of production at 7 million euros confirm the constant development of iVision and the Group. The desire to grow through external lines, as indicated in the IPO phase, is demonstrated by the recent acquisitions that guarantee consolidation of the business.”

Although the data relating to the recent acquisitions of Ivilens OOD and Teknoema are not yet consolidated in the half-year ended June 30, 2024, the Company expects their impact to be reflected in the year-end results, thanks to the synergies that will arise from them.

“We confirm our commitment to the growth path already outlined at our IPO,” said Stefano Fulchir, CEO of iVision Tech. “ To support these developments, we have chosen to diversify our funding by preparing an innovative instrument, the Minibond, which allows us to gradually draw on new funding based on operational needs, further strengthening our presence on international markets and expanding our offering with new products.”

__

(Featured image by Ibrahim Mansoor via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Crowdfunding buzz. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us